美国 FDA 解除了对 Nurix Therapeutics 的 NX-2127 1 期试验的部分临床搁置，从而能够重新启动注册。 US FDA lifts partial clinical hold on Nurix Therapeutics' NX-2127 Phase 1 trial, enabling enrollment restart.

Nurix Therapeutics 宣布美国 FDA 取消了对其 NX-2127 一期试验的部分临床搁置，允许该公司重新启动该研究的注册。 Nurix Therapeutics announced that the US FDA has lifted the partial clinical hold on its NX-2127 Phase 1 trial, allowing the company to reinitiate enrollment in the study. 在该公司向 FDA 传达其打算过渡到改进的制造工艺后，该公司暂停了该计划。 The hold was placed following the company's communication to the FDA of its intention to transition to an improved manufacturing process. 该研究旨在评估 NX-2127 对患有复发/难治性 B 细胞恶性肿瘤的成人患者的疗效。 The study aims to evaluate NX-2127 in adults with relapsed/refractory B-cell malignancies.